Zymeworks Inc. (NASDAQ:ZYME) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET

Company Participants

Shrinal Inamdar - Director, Investor Relations
Bijal Desai - Vice President-Finance & Strategy
Paul Moore - Chief Scientific Officer
Ken Galbraith - Chair & Chief Executive Officer
Pranshul Chauhan - Associate Medical Director

Conference Call Participants

Stephen Willey - Stifel
Jon Miller - Evercore
Robert Burns - H.C. Wainwright

Operator

Thank you for standing by. This is the conference operator. Welcome to Zymeworks Second Quarter 2024 Results Conference Call and Webcast. As a reminder, all participants are in a listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]

I would now like to turn the conference over to Shrinal Inamdar, Director of Investor Relations. Shrinal, please go ahead.

Shrinal Inamdar

Thank you, operator. Good afternoon, and thank you for joining our second quarter 2024 results conference call. Before we begin, I would like to remind you that we'll be making a number of forward-looking statements during this call, including without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary.

Forward-looking statements are based on our current expectations and various assumptions, and are subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as part of the SEC.

In a moment, I will hand over to Bijal Desai, our VP of Finance and Strategy, who will be discussing recent corporate updates, along with our financial results for the second quarter 2024. Following this, Dr. Paul Moore, our Chief Scientific Officer, will talk about key highlights for our second quarter, including the investigational new drug application therapies, ZW171 and ZW191 by the FDA.

At the end of the call, Bijal, Paul and Ken Galbraith, our Chair and CEO, will be available for Q&A as well as Pranshul Chauhan, Associate Medical Director for early-stage development for ZW171.

As a reminder, the audio and slides from this call will also be available on the Zymeworks website later today.

I will now turn the call over to Bijal.

Bijal Desai

Thanks, Shrinal, and thank you, everyone, for joining us today for our second quarter 2024 earnings call. I will begin today's call with an overview of key achievements from our development programs as well as our financial results.